medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2006, Number S1

<< Back Next >>

Ann Hepatol 2006; 5 (S1)

Module Xlll
Treatment of hepatitis C virus infection and renal disease

Méndez-Sánchez N

Language: English
References: 25
Page: 53-55
PDF size: 45.43 Kb.


Text Extraction

Renal diseases occur frequently in patients chronically infected by hepatitis C virus (HCV). These may be causes or consequences of HCV infection. The prevalence of HCV infection in patients receiving hemodialysis is 6.7% to 10.2% in some centers in Mexico. However, the problem may be greater than these percentages suggest because the prevalence of HCV infection is as high as 50% in some countries. HCV infection frequently results in kidney damage. Membranoproliferative glomerulonephritis with or without cryoglobulinemia is the most significant renal disease associated with hepatitis C, followed by membranous nephropathy and hepato–renal syndrome. Treatment of renal disease patients for HCV infection improves several parameters of renal function, particularly in patients with membranoproliferative glomerulonephritis and cryoglobulinemia.


REFERENCES

  1. Mendez-Sanchez N, Motola-Kuba D, Chavez-Tapia NC, Bahena J, Correa-Rotter R, Uribe M. Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol 2004; 42: 43212. [PMID: 15365034]

  2. Gonzalez-Michaca L, Soto-Ramirez LE, Rodriguez R, Gamba G. Viral hepatitis C in patients with terminal chronic renal insufficiency. III. Viral quantification. Rev Invest Clin 2001; 53: 21-7. [PMID: 11332047]

  3. Casanovas-Taltavull T, Baliellas C, Benasco C, Serrano TT, Casanova A, Perez JL, Guerrero L, Gonzalez MT, Andres E, Gil-Vernet S, Casais LA. Efficacy of interferon for chronic hepatitis C virus-related hepatitis in kidney transplant candidates on hemodialysis: results after transplantation. Am J Gastroenterol 2001; 96: 1170-7. [PMID: 11316166]

  4. Medina J, Garcia-Buey L, Moreno-Otero R. Hepatitis C virusrelated extra-hepatic disease–aetiopathogenesis and management. Aliment Pharmacol Ther 2004; 20: 129-41. [PMID: 15233692]

  5. Alric L, Plaisier E, Thebault S, Peron JM, Rostaing L, Pourrat J, Ronco P, Piette JC, Cacoub P. Influence of antiviral therapy in hepatitis C virus-associated cryoglobulinemic MPGN. Am J Kidney Dis 2004; 43: 617-23. [PMID: 15042538]

  6. Contreras AM, Vargas-Frutos E. Hepatitis viral C en patients con insuficiencia renal crónica, in Conceptos actuales en Hepatitis C, Mendez-Sanchez N, Uribe M, Editors. México: Mc Graw-Hill, 2005, p. 203–216.

  7. Fabrizi F, Martin P, Bunnapradist S. Treatment of chronic viral hepatitis in patients with renal disease. Gastroenterol Clin North Am 2004; 33: 655-70, xi. [PMID: 15324949]

  8. Nakayama E, Akiba T, Marumo F, Sato C. Prognosis of antihepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol 2000; 11: 1896-902. [PMID: 11004221]

  9. Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Meta-analysis: Effect of hepatitis C virus infection on mortality in dialysis. Aliment Pharmacol Ther 2004; 20: 1271-7. [PMID: 15606388]

  10. Bruchfeld A, Wilczek H, Elinder CG. Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004; 78: 745-50. [PMID: 15371680]

  11. Periera BJ, Wright TL, Schmid CH, Levey AS. The impact of pretransplantation hepatitis C infection on the outcome of renal transplantation. Transplantation 1995; 60: 799-805. [PMID: 7482738]

  12. Fabrizi F, Dulai G, Dixit V, Bunnapradist S, Martin P. Metaanalysis: interferon for the treatment of chronic hepatitis C in dialysis patients. Aliment Pharmacol Ther 2003; 18: 1071-81. [PMID: 14653826]

  13. Thevenot T, Regimbeau C, Ratziu V, Leroy V, Opolon P, Poynard T. Meta-analysis of interferon randomized trial in the treatment of viral hepatitis C in naive patients: 1999 update. J Viral Hepat 2001; 8: 48-62. [PMID: 11155152]

  14. Russo MW, Goldsweig CD, Jacobson IM, Brown RS, Jr. Interferon monotherapy for dialysis patients with chronic hepatitis C: an analysis of the literature on efficacy and safety. Am J Gastroenterol 2003; 98: 1610-5. [PMID: 12873587]

  15. Chen YK, Bala K. Treatment of chronic hepatitis C with recombinant interferon alfa. West J Med 1992; 156: 72. [PMID: 1734608]

  16. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, Miglioli M, Barbara L. A pilot study of combination therapy with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology 1994; 107: 812-7. [PMID: 7521308]

  17. Mousa DH, Abdalla AH, Al-Shoail G, Al-Sulaiman MH, Al-Hawas FA, Al-Khader AA. Alpha-interferon with ribavirin in the treatment of hemodialysis patients with hepatitis C. Transplant Proc 2004; 36: 1831-4. [PMID: 15350490]

  18. Meyers CM, Seeff LB, Stehman-Breen CO, Hoofnagle JH. Hepatitis C and renal disease: an update. Am J Kidney Dis 2003; 42: 631-57. [PMID: 14520615]

  19. Sporea I, Sirli R, Golea O, Totolici C, Danila M, Popescu A. Peginterferon alfa 2a (40 kDa) in patients on chronic haemodialysis with chronic C hepatitis. Preliminary results. Rom J Gastroenterol 2004; 13: 99-102. [PMID: 15229772]

  20. Potthoff A, Wiegand J, Luth JB, Wedemeyer H, Manns MP, Tillmann HL. Superiority of standard interferon-alpha2b compared to pegylated interferon-alpha2b (12 kDa) in a hemodialysis patient with chronic hepatitis C? Clin Nephrol 2005; 63: 232-5. [PMID: 15786827]

  21. Mukherjee S, Gilroy RK, McCashland TM, Schafer DF. Pegylated interferon for recurrent hepatitis C in liver transplant recipients with renal failure: a prospective cohort study. Transplant Proc 2003; 35: 1478-9. [PMID: 12826198]

  22. Teta D, Luscher BL, Gonvers JJ, Francioli P, Phan O, Burnier M. Pegylated interferon for the treatment of hepatitis C virus in haemodialysis patients. Nephrol Dial Transplant 2005; 20: 991-3. [PMID: 15741205]

  23. Mathurin P, Mouquet C, Poynard T, Sylla C, Benalia H, Fretz C, Thibault V, Cadranel JF, Bernard B, Opolon P, Coriat P, Bitker MO. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology 1999; 29: 257-63. [PMID: 9862875]

  24. Fabrizi F, Lunghi G, Marai P, Marcelli D, Guarnori I, Raffaele L, Erba G, Pagano A, Locatelli F. Virological and histological features of hepatitis C virus (HCV) infection in kidney transplant recipients. Nephrol Dial Transplant 1996; 11: 159-64. [PMID: 8649626]

  25. Jefferson JA, Johnson RJ. Treatment of hepatitis C-associated glomerular disease. Semin Nephrol 2000; 20: 286-92. [PMID: 10855938]




2020     |     www.medigraphic.com